Beatriz Mendes Awni Cidale

Beatriz Mendes Awni Cidale


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2022 in medRxiv
Verified
Preprint
Open access
PDF file
CXCamila Bragança Xavier
Camila Bragança Xavier
CLCarlos Diego H. Lopes
Carlos Diego H. Lopes
BCBeatriz Mendes Awni Cidale
Beatriz Mendes Awni Cidale
ECEduardo F. Campos
Eduardo F. Campos
JAJoão Pedro B. Alves
João Pedro B. Alves
DJDenis Leonardo Fontes Jardim
Denis Leonardo Fontes Jardim
Purpose: Solid tumors harboring tumor mutational burden (TMB) ≥ 10 mutations per megabase (mut/Mb) received agnostic approval for pembrolizumab. However, TMB cut-off alone is not a predictor of overall survival (OS). This work aims to analyze the somatic mutational profile’s influence in the outcomes of patients with TMB-high tumors treated with immune checkpoint inhibitors (ICIs). Methods: This post-hoc analysis evaluated clinical and molecular features of 1,661 patients with solid tumors treated with ICIs. We performed OS analysis for TMB thresholds of ≥ 10, ≥ 20, and < 10 mut/Mb. For a TMB ≥ 10mut/Mb cutoff, we assessed OS according to mutational profile. For genes exhibiting a correlation with OS (P < 0.05) at the univariate assessment, we conducted a Cox multivariate analysis adjusted by median TMB, sex, age, microsatellite instability (MSI), and histology. Results: 1,661 patients were investigated, and 488 harbored a TMB ≥ 10 mut/Mb (29.4%). The median OS was 42 months for TMB ≥ 10 or 20 mut/Mb, and 15 months for TMB < 10 mut/Mb (P < 0.005). In patients harboring TMB ≥ 10mut/Mb, mutations in E2F3 or STK11 were correlated with worse OS, and mutations in NTRK3, PTPRD, RNF43, TENT5C, TET1 or ZFHX3 with better OS. These associations were confirmed by univariate and multivariate analyses (P < 0.05). Melanoma histology and TMB above the median endowed patients with better OS (P < 0.05). MSI status, age, and gender did not have a consistent statistically significant effect on OS Conclusion: Combining TMB information and mutation profiles in key cancer genes can be used to better qualify patients for ICI treatment and predict their OS. CONTEXT SUMMARY: Key objective: Tumor mutational burden (TMB) of ≥ 10 mutations per megabase (mut/Mb) grant agnostic indication of pembrolizumab for advanced solid tumors’ treatment, however a substantial number of patients do not respond to therapy. This work aims to analyze the somatic mutational profile’s influence in the outcomes of patients with TMB ≥ 10mut/Mb tumors treated with ICIs. Knowledge generated: Mutation profile can modify survival outcomes to ICIs in patients with TMB ≥ 10 mut/Mb. Mutations in E2F3 or STK11 correlate with worse OS, while mutations in NTRK3, PTPRD, RNF43, TENT5C, TET1 or ZFHX3 correlate with better OS in TMB-high patients receiving ICIs. Relevance: We found that the combination of a high TMB and the somatic mutational profile in key cancer genes can be decisive in better qualify patients for ICI treatment.

23 July 2024 in Medical Sciences
Verified
Journal Article
Open access
PDF file
DJDomingos Sávio Do Rego Lins Junior
Domingos Sávio Do Rego Lins Junior
BCBeatriz Mendes Awni Cidale
Beatriz Mendes Awni Cidale
APAna Zelia Leal Pereira
Ana Zelia Leal Pereira
JMJacqueline Nunes de Menezes
Jacqueline Nunes de Menezes
EBEduardo Bertolli
Eduardo Bertolli
RMRodrigo Ramella Munhoz
Rodrigo Ramella Munhoz
Patients with cutaneous malignancies and locoregional involvement represent a high-risk population for disease recurrence, even if they receive optimal surgery and adjuvant treatment. Here, we discuss how neoadjuvant therapy has the potential to offer significant advantages over adjuvant treatment, further improving outcomes in some patients with skin cancers, including melanoma, Merkel cell carcinoma, and cutaneous squamous-cell carcinoma. Both preclinical studies and in vivo trials have demonstrated that exposure to immunotherapy prior to surgical resection can trigger a broader and more robust immune response, resulting in increased tumor cell antigen presentation and improved targeting by immune cells, potentially resulting in superior outcomes. In addition, neoadjuvant approaches hold the possibility of providing a platform for evaluating pathological responses in the resected lesion, optimizing the prognosis and enabling personalized adaptive management, in addition to expedited drug development. However, more data are still needed to determine the ideal patient selection and the best treatment framework and to identify reliable biomarkers of treatment responses. Although there are ongoing questions regarding neoadjuvant treatment, current data support a paradigm shift toward considering neoadjuvant therapy as the standard approach for selecting patients with high-risk skin tumors.

4 March 2022 in Case Reports in Oncology
Verified
Journal Article
Open access
PDF file
BCBeatriz Mendes Awni Cidale
Beatriz Mendes Awni Cidale
CLCarlos Diego H Lopes
Carlos Diego H Lopes
GHGuilherme Harada
Guilherme Harada
ASAlessandra Corte Real Salgues
Alessandra Corte Real Salgues
GFGilmar de Andrade França
Gilmar de Andrade França
RMRodrigo Ramella Munhoz
Rodrigo Ramella Munhoz
Werner’s syndrome is caused by the inactivation of both WRN alleles and is characterized by premature aging and increased risk of neoplasms, especially those of mesenchymal origins, such as sarcomas. Given the characteristic genomic instability, patients with this syndrome are more susceptible to develop toxicities when exposed to cytotoxic agents, such as alkylators and anthracyclines. The impact of the monoallelic WRN mutation on treatment-associated toxicities is poorly understood. Here, we report a patient with locally advanced dedifferentiated liposarcoma of the retroperitoneum harboring a heterozygous germline inactivation mutation in the WRN gene, who was treated with a classic regimen of ifosfamide and doxorubicin and developed exacerbated and prolonged hematological and renal toxicities.

25 January 2026 in Brazilian Journal of Oncology
Verified
Journal Article
Open access
VGVanessa Anne Mohr-Bell Giachetti
Vanessa Anne Mohr-Bell Giachetti
ISIsabela Paulino Serur
Isabela Paulino Serur
FBFelipe de Galiza Barbosa
Felipe de Galiza Barbosa
BCBeatriz Mendes Awni Cidale
Beatriz Mendes Awni Cidale
GKGabriela Franco Katz
Gabriela Franco Katz
RMRodrigo Ramella Munhoz
Rodrigo Ramella Munhoz
Melanoma is regarded as a highly aggressive skin cancer due to its potential for early metastasis and poor outcomes in advanced stages. Early detection, accurate staging, follow-up imaging, and assessment of treatment response are critical for improving survival rates in melanoma patients. Positron-emission tomography/computed tomography (PET/CT), particularly utilizing 18F-fluorodeoxyglucose (18F-FDG), has become a gold standard imaging modality in the comprehensive management of melanoma. This review critically examines the current literature on the utility of PET/CT in melanoma, focusing on its diagnostic and prognostic role, current indications and rational use. By synthesizing evidence from recent studies, this article highlights the strengths and limitations of PET/CT in clinical practice and explores future directions for research in the field.

16 May 2024 in Brazilian Journal of Oncology
Verified
Journal Article
Open access
NLNildevande Firmino Lima
Nildevande Firmino Lima
MQMarcello Moro Queiroz
Marcello Moro Queiroz
JFJulia Sousa Leal Franco
Julia Sousa Leal Franco
JLJulia Sousa Lins
Julia Sousa Lins
ECEduardo Felício de Campos
Eduardo Felício de Campos
RMRodrigo Ramella Munhoz
Rodrigo Ramella Munhoz
Recognition of the molecular basis of gastrointestinal stromal tumors has paved the way for significant breakthroughs in the diagnosis and treatment of this disease as well as positioned gastrointestinal stromal tumors as a framework for the concept of precision oncology in solid tumors. The incorporation of novel targeted agents for molecularly defined subgroups has led to significant improvements in treatment outcomes; however, the characterization of heterogeneous KIT or PDGFRA mutations and the emergence of resistance mechanisms highlight the need for a broader use of comprehensive molecular profiling and emphasize the importance of molecularly driven adaptive treatment strategies. Such a molecular background is critical for developing personalized and effective interventions and optimizing outcomes. The present review summarizes key studies that provide the basis for standard-of-care management options as well as provides molecular insights into the management of gastrointestinal stromal tumors, with an emphasis on recent advances.

25 January 2026 in Brazilian Journal of Oncology
Verified
Journal Article
Open access
BCBeatriz Mendes Awni Cidale
Beatriz Mendes Awni Cidale
GZGiulia Kodja Zanetta
Giulia Kodja Zanetta
GOGustavo Benfatti Olivato
Gustavo Benfatti Olivato
ISIsabela Paulino Serur
Isabela Paulino Serur
VAVitor Dias de Almeida
Vitor Dias de Almeida
RMRodrigo Ramella Munhoz
Rodrigo Ramella Munhoz
Uveal melanoma (UM) is a rare malignancy with poor outcomes in the metastatic setting and limited benefit from conventional systemic therapies. Tebentafusp, a novel bispecific fusion protein targeting glycoprotein 100 (gp100) in human leukocyte antigen A (HLA-A)*02:01–positive patients, has recently demonstrated a survival advantage, being approved in Brazil in 2025. However, its distinct toxicity profile, particularly cytokine-release syndrome, rash, and liver enzyme elevations, remain unfamiliar to many clinicians. Reporting early real-world experiences can provide valuable practical guidance for managing these adverse events in routine practice. In this case series, we describe four adult HLA-A*02:01–positive patients with metastatic UM treated with tebentafusp at a single Brazilian center. All participants initiated therapy in an inpatient setting following standardized institutional routines designed for safe administration, including structured premedication, continuous monitoring, and predefined response algorithms for early infusion reactions. Across cases, predictable early reactions were successfully managed using protocol-based interventions—such as antihistamines, low-dose corticosteroids, intravenous fluids, and targeted supportive care—allowing uninterrupted dose escalation and subsequent transition to outpatient treatment. These cases illustrate the practical steps, decision pathways, and monitoring strategies that enable safe implementation of tebentafusp in real-world practice. This case series highlights the characteristic toxicities associated with tebentafusp and emphasizes the importance of early recognition and proactive management strategies to ensure treatment continuation. Our experience provides pragmatic insights that may support oncologists in Brazil as they begin to integrate tebentafusp into the care of patients with metastatic UM.